Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug

Amgen’s Tepezza Receives Approval in Japan for Treating Thyroid Eye Disease

Fineline Cube Sep 25, 2024

Amgen (NASDAQ: AMGN), a prominent biotechnology company based in the U.S., has announced that its...

Company

GSK Appoints Li Weidong as Vaccine Business Head for China

Fineline Cube Sep 25, 2024

GSK plc (LON: GSK, NYSE: GSK), a leading pharmaceutical company based in the UK, has...

Company Deals

Beijing Bohui Innovation Biotechnology Ends Rabies Vaccine Partnership with BOAOVAX

Fineline Cube Sep 25, 2024

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHA: 300318), a leading biopharmaceutical company in China,...

Company Deals

Nona Biosciences Partners with Alkyon Therapeutics to Develop Next-Generation Immunotherapies

Fineline Cube Sep 25, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Drug

Elevation Oncology’s Claudin 18.2 Targeting ADC Earns FDA Fast Track Designation for Gastric Cancer

Fineline Cube Sep 25, 2024

Elevation Oncology, Inc. (NASDAQ: ELEV), a biopharmaceutical company based in the U.S., has announced that...

Company Deals

Beijing Bohui Innovation and BOAOVAX End Collaboration on Rabies Vaccine Development

Fineline Cube Sep 25, 2024

Beijing Bohui Innovation Biotechnology Group Co., Ltd. (SHE: 300318), a biopharmaceutical company based in China,...

Company

InnoCare Pharma’s H1 2024 Revenue Boosted by Orelabrutinib, Anticipates Minjuvi Approval in 2025

Fineline Cube Sep 25, 2024

InnoCare Pharma (HKG: 9969; SHA: 688428), a biopharmaceutical company based in China, has released its...

Company Drug

China Medical System’s Opzelura Cream Filing for Vitiligo Accepted by NMPA

Fineline Cube Sep 25, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that its market filing for Opzelura...

Company Drug

Junshi Biosciences’ Toripalimab Secures EC Nod for Two Cancer Indications

Fineline Cube Sep 25, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...

Company Drug

Allist Pharma’s Partner Abbisko Receives NMPA Green Light for NSCLC Drug Trial

Fineline Cube Sep 25, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...

Company Medical Device

Huadong Medicine’s V20 Device Receives NMPA Approval for Market Launch

Fineline Cube Sep 25, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...

Company Deals

Winner Medical Expands Global Footprint with Acquisition of Global Resources International

Fineline Cube Sep 25, 2024

China-based Winner Medical Co., Ltd., a prominent manufacturer of disposable medical products, has announced the...

Company

AstraZeneca Launches South Korea Innovation Program with Focus on Chinese Market Expansion

Fineline Cube Sep 24, 2024

AstraZeneca plc (LON: AZN, Nasdaq: AZN), a UK-based pharmaceutical and biopharmaceutical company, is reportedly launching...

Company Drug

UCB’s Bimzelx Gains FDA Approval for Three Additional Autoimmune Indications

Fineline Cube Sep 24, 2024

Belgium-based biopharmaceutical company UCB has announced that the US Food and Drug Administration (FDA) has...

Company Drug

HBOW Bio’s First-in-Class Tumor Imaging Drug NC527-X Receives NMPA Clinical Trial Approval

Fineline Cube Sep 24, 2024

HBOW Bio, a precision oncology company supported by Sherpa Healthcare Partners, has secured clinical trial...

Company Drug

CDE’s BL-B01D1 on Track for Breakthrough Therapy Designations for EGFR Wild-Type and Mutant NSCLC

Fineline Cube Sep 24, 2024

The Center for Drug Evaluation (CDE) has indicated on its website that two indications for...

Company Medical Device

Acotec Scientific’s Heart Valve Balloon Dilatation Catheter RunFlow Wins NMPA Approval

Fineline Cube Sep 24, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), a leading medical device company based in China, has...

Company Deals

AimingMed Technologies Partners with RekeyMed to Advance Biotech and Organoid Innovations

Fineline Cube Sep 24, 2024

Hangzhou AimingMed Technologies Co., Ltd., a leading organoid specialist based in China, has entered into...

Company Drug

Shanghai Fudan-Zhangjiang Enrolls First Patient in U.S. Phase II Study for Port Wine Stain Treatment

Fineline Cube Sep 24, 2024

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a leading biopharmaceutical company based in...

Company Drug

Antengene’s Xpovio Receives NDA Approval in Thailand for Multiple Myeloma Treatment

Fineline Cube Sep 24, 2024

Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...

Posts pagination

1 … 344 345 346 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.